# EDGAR Filing Document

**Accession Number:** 0001464165
**File Stem:** 0001477932-26-002155
**Filing Date:** 2026-4
**Character Count:** 59811
**Document Hash:** 2d66168bcf38dfa83f7ba306b1d07637
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001477932-26-002155.hdr.sgml**: 20260413

**ACCESSION NUMBER**: 0001477932-26-002155

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 21

**CONFORMED PERIOD OF REPORT**: 20260413

**FILED AS OF DATE**: 20260413

**DATE AS OF CHANGE**: 20260413

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BetterLife Pharma Inc.
- **CENTRAL INDEX KEY:** 0001464165
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0131

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 333-161157
- **FILM NUMBER:** 26857324

**BUSINESS ADDRESS:**
- **STREET 1:** 1275 WEST 6TH AVENUE
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6H 1A6
- **BUSINESS PHONE:** 438-884-8841

**MAIL ADDRESS:**
- **STREET 1:** 1275 WEST 6TH AVENUE
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6H 1A6

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Pivot Pharmaceuticals Inc.
- **DATE OF NAME CHANGE:** 20150417

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Neurokine Pharmaceuticals Inc.
- **DATE OF NAME CHANGE:** 20090514

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER** 

**PURSUANT TO RULE 13a-16 OR 15d-16 OF THE** 

**SECURITIES EXCHANGE ACT OF 1934**

For the month of April, 2026.

Commission File Number 333-161157

---

| |
|:---|
| **BETTERLIFE PHARMA INC.** |
| (Translation of registrant's name into English) |

---

**1275 WEST 6<sup>TH</sup> AVENUE, #300**

**VANCOUVER, BC CANADA V6H 1A6**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

**Note:** Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

**Note:** Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

**Exhibits:**

---

| | |
|:---|:---|
| [99.1](betrf_ex991.htm) | [News Release dated April 10, 2026](betrf_ex991.htm) |
| [99.2](betrf_ex992.htm) | [News Release dated April 8, 2026](betrf_ex992.htm) |
| [99.3](betrf_ex993.htm) | [News Release dated April 2, 2026](betrf_ex993.htm) |
| [99.4](betrf_ex994.htm) | [News Release dated February 23, 2026](betrf_ex994.htm) |
| [99.5](betrf_ex995.htm) | [News Release dated January 6, 2026](betrf_ex995.htm) |
| [99.6](betrf_ex996.htm) | [News Release dated December 23, 2025](betrf_ex996.htm) |
| [99.7](betrf_ex997.htm) | [News Release dated December 11, 2025](betrf_ex997.htm) |
| [99.8](betrf_ex998.htm) | [News Release dated December 4, 2025](betrf_ex998.htm) |
| [99.9](betrf_ex999.htm) | [Material Change Report dated December 2, 2025](betrf_ex999.htm) |

---

2<br>

**SIGNATURES**

Pursuant to the requirements of the *Securities Exchange Act of 1934*, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **BETTERLIFE PHARMA INC.** | **BETTERLIFE PHARMA INC.** |
| Date: April 13, 2026 | By: | */s/ Moira Ong* |
|  |  | Name: Moira Ong |
|  |  | Title: Chief Financial Officer |

---

3<br>

## Exhibit 99.1

**EXHIBIT 99.1**

![](betrf_ex991img1.jpg)

**BetterLife Pharma Announces Issuance of Shares and Extension of Convertible Debentures**

VANCOUVER, British Columbia, April 10, 2026 - BetterLife Pharma Inc. ("BetterLife" or the "Company") (<u>CSE: BETR</u> / <u>OTCQB: BETRF</u> / FRA: <u>NPAU</u>), an emerging biotech company, announces that it has issued 600,000 common shares to a third party corporate advisor for services rendered beginning October 2025. In addition, the Company has extended maturity dates of convertible debentures issued on February 29, and March 28, 2024. Original maturity dates were February 28, 2026 and March 28, 2026, which have been extended for a further one (1) year term from original maturity.

**About BetterLife Pharma** 

BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing BETR-001 to treat various neurological disorders. BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. BetterLife's synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of various neurological disorders, until around 2042.

BetterLife also owns a drug candidate for the treatment of viral infections and is in the process of seeking strategic alternatives for further development.

For further information, please visit <u>BetterLife Pharma</u>.

**Contact**

Ahmad Doroudian, Chief Executive Officer

Email: <u>Ahmad.Doroudian@blifepharma.com</u>

Phone: 1-604-221-0595

**Cautionary Note Regarding Forward-Looking Statements**

No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release may contain forward-looking statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

## Exhibit 99.2

**EXHIBIT 99.2**

![](betrf_ex992img1.jpg)

**BetterLife Announces Private Placement Offering of Units**

VANCOUVER, British Columbia, April 8, 2026 - BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: <u>BETR</u> / OTCQB: <u>BETRF</u> / FRA: <u>NPAU</u>), an emerging biotech company focused on the development and commercialization of non-hallucinogenic LSD-based therapeutics for mental disorders, announces that it intends to complete a non-brokered private placement offering (the "Private Placement") of up to $500,000. The Private Placement will comprise of units issued at a price of $0.07 per unit, with each unit consisting of one common share in the capital of the Company ("Common Share") and one full common share purchase warrant ("Warrant"). Each Warrant will entitle the holder to purchase one Common Share at an exercise price of $0.10 for up to two years following the date of the closing of the Private Placement.

The Company intends to use the proceeds for the advancement of its lead compound BETR-001, a non-hallucinogenic derivative of LSD (lysergic acid diethylamide), and general working capital purposes.

The Offering is expected to close on or about April 17, 2026 and is subject to execution of subscription agreements by the placees and to certain conditions including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the Canadian Securities Exchange.

All securities issued in connection with the Offering will be subject to a four month and one day statutory resale restriction pursuant to applicable Canadian securities laws.

**About BetterLife Pharma** 

BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing BETR-001 to treat various neurological disorders. BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. BetterLife's synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of various neurological disorders, until around 2042.

BetterLife also owns a drug candidate for the treatment of viral infections and is in the process of seeking strategic alternatives for further development.

For further information, please visit <u>BetterLife Pharma</u>.

**Contact**

Ahmad Doroudian, Chief Executive Officer

Email: <u>Ahmad.Doroudian@blifepharma.com</u>

Phone: 1-604-221-0595

**Cautionary Note Regarding Forward-Looking Statements**

No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements including, but not limited to, closing of a private placement and approval of the Canadian Securities Exchange, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

## Exhibit 99.3

**EXHIBIT 99.3**

![](betrf_ex993img1.jpg)

**BetterLife Pharma Announces Debt Conversions**

VANCOUVER, British Columbia, April 2, 2026 - BetterLife Pharma Inc. ("BetterLife" or the "Company") (<u>CSE: BETR</u> / <u>OTCQB: BETRF</u> / FRA: <u>NPAU</u>), an emerging biotech company, announces that it has issued 2,153,205 common shares and 2,153,205 share purchase warrants in connection with the conversion of principal and accrued interest on convertible debentures totaling $215,320.55. Each share purchase warrant entitles the holder to acquire one common share at an exercise price of $0.10 per share and will expire between September 27 and October 29, 2026.

**About BetterLife Pharma** 

BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing BETR-001 to treat various neurological disorders. BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. BetterLife's synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of various neurological disorders, until around 2042.

BetterLife also owns a drug candidate for the treatment of viral infections and is in the process of seeking strategic alternatives for further development.

For further information, please visit <u>BetterLife Pharma</u>.

**Contact**

Ahmad Doroudian, Chief Executive Officer

Email: Ahmad.Doroudian@blifepharma.com

Phone: 1-604-221-0595

**Cautionary Note Regarding Forward-Looking Statements**

No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

## Exhibit 99.4

**EXHIBIT 99.4**

![](betrf_ex994img1.jpg)

**BetterLife Announces Stock Option Grant**

VANCOUVER, British Columbia, February 23, 2026 - BetterLife Pharma Inc. ("BetterLife" or the "Company") (<u>CSE: BETR</u> / <u>OTCQB: BETRF</u> / FRA: <u>NPAU</u>), an emerging biopharmaceutical company focused on development of BETR-001, its proprietary non-hallucinogenic derivative of lysergic acid diethylamide ("LSD") for the treatment of neurological disorders, today announced that it has granted an aggregate of 6,050,000 options to purchase Common Shares ("Options") to its directors, officers and employees. Each Option is exercisable upon vesting to acquire one common share of the Company at a price of $0.055 per share for a period of five years, with the Options vesting in four equal tranches on the date of grant, and 6, 12 and 18-month anniversaries of the date of grant.

**About BetterLife Pharma** 

BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing BETR-001 to treat various neurological disorders. BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. BetterLife's synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of various neurological disorders, until around 2042.

BetterLife also owns a drug candidate for the treatment of viral infections and is in the process of seeking strategic alternatives for further development.

For further information, please visit <u>BetterLife Pharma</u>.

**Contact**

Ahmad Doroudian, Chief Executive Officer

Email: <u>Ahmad.Doroudian@blifepharma.com</u>

Phone: 1-604-221-0595

**Cautionary Note Regarding Forward-Looking Statements**

No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

## Exhibit 99.5

**EXHIBIT 99.5**

![](betrf_ex995img1.jpg)

**BetterLife Pharma to Participate in YAFO Capital Access Asia Partnering Forum During JPM Week in San Francisco** 

VANCOUVER, British Columbia, January 6, 2026 - BetterLife Pharma Inc. ("BetterLife" or the "Company") (<u>CSE: BETR</u> / <u>OTCQB: BETRF</u> / FRA: <u>NPAU</u>), an emerging biopharmaceutical company focused on development of BETR-001, its proprietary non-hallucinogenic derivative of lysergic acid diethylamide ("LSD") for the treatment of neurological disorders, today announced that it will be participating in the YAFO Capital Access Asia 2025 Partnering Forum, held in San Francisco, California, during JPM Week.

The YAFO Capital Access Asia Partnering Forum brings together innovative life science companies and leading investors, pharmaceutical partners, and strategic advisors, with a particular focus on fostering collaboration between North American and Asian capital and industry partners.

In addition to the YAFO Capital event on January 11<sup>th</sup>, Dr. Ahmad Doroudian Chief Executive Officer, will attend the following events:

- H7 Life science Investment Forum & China Night Reception on January 12th, <br> - WuXi Global Forum 2026 on January 13th, and <br> - DARPA and Ferocity Capital Biodefence Summit on January 13th.

Dr. Ahmad Doroudian will represent BetterLife and will be available for one-on-one meetings with investors, potential partners, and other stakeholders to discuss the Company's development strategy for BETR-001.

Parties interested in scheduling a meeting with BetterLife during the YAFO Capital Access Asia Partnering Forum are encouraged to contact Dr. Ahmad Doroudian at the email address below.

BETR-001, a potent neuroplastogen, is BetterLife's patented stereoisomer of 2-bromo-LSD, a non-hallucinogenic derivative of LSD under development for the potential treatment of traumatic brain injury, post traumatic stress disorder and cluster headache. Previous forms of 2-bromo-LSD has been shown to be non-hallucinogenic, safe and tolerable in man, and in a small clinical study, to cause meaningful reduction in cluster headache frequency (Karst et al, Cephalgia 2010).

1<br>

**About BetterLife Pharma** 

BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing BETR-001 to treat various neurological disorders. BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. BetterLife's synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of various neurological disorders, until around 2042.

BetterLife also owns a drug candidate for the treatment of viral infections and is in the process of seeking strategic alternatives for further development.

For further information, please visit <u>BetterLife Pharma</u>.

**Contact**

Ahmad Doroudian, Chief Executive Officer

Email: <u>Ahmad.Doroudian@blifepharma.com</u>

Phone: 1-604-221-0595

**Cautionary Note Regarding Forward-Looking Statements**

No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

2<br>

## Exhibit 99.6

**EXHIBIT 99.6**

![](betrf_ex996img1.jpg)

**BetterLife Pharma Announces Director Resignation**

VANCOUVER, British Columbia, December 23, 2025 - BetterLife Pharma Inc. ("BetterLife" or the "Company") (<u>CSE: BETR</u> / <u>OTCQB: BETRF</u> / FRA: <u>NPAU</u>), an emerging biotech company, today announced the resignation of Mr. Robert Metcalfe from the Company's board of directors. Mr. Metcalfe served as a director and chairman of the audit committee for past 6 years.

"We would like to express our gratitude to Robert for his years of dedicated service to BetterLife shareholders. He consistently provided wise counsel to our team and we wish him the best in his future endeavors. We will be searching for new director candidates in the near future as we advance BetterLife's plans," said Dr. Ahmad Doroudian, Chief Executive Officer of the Company.

**About BetterLife Pharma** 

BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing BETR-001 to treat various neurological disorders. BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. BetterLife's synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of various neurological disorders, until around 2042.

BetterLife also owns a drug candidate for the treatment of viral infections and is in the process of seeking strategic alternatives for further development.

For further information, please visit <u>BetterLife Pharma</u>.

**Contact**

Ahmad Doroudian, Chief Executive Officer

Email: <u>Ahmad.Doroudian@blifepharma.com</u>

Phone: 1-604-221-0595

**Cautionary Note Regarding Forward-Looking Statements**

No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

## Exhibit 99.7

**EXHIBIT 99.7**

![](betrf_ex997img1.jpg)

**BetterLife Pharma Announces Engagement with Shanghai-Based YAFO Capital**

VANCOUVER, British Columbia, December 11, 2025 - BetterLife Pharma Inc. ("BetterLife" or the "Company") (<u>CSE: BETR</u> / <u>OTCQB: BETRF</u> / FRA: <u>NPAU</u>), an emerging biotech company focused on development of BETR-001, its proprietary non-hallucinogenic derivative of lysergic acid diethylamide ("LSD"), is pleased to announce it has signed an engagement agreement with Shanghai-based YAFO Capital ("YAFO"), as its exclusive advisor to seek strategic partnerships for development of BETR-001 in the Greater China regions, including mainland China, Hong Kong, Taiwan and Macau. Pursuant to the agreement, BetterLife intends to retain YAFO on a non-exclusive basis for territories outside of Greater China.

Dr. Ahmad Doroudian, CEO of BetterLife, commented, "We are excited to work with the YAFO team to establish partnerships for the development of BETR-001 and to bring potential non-hallucinogenic treatments for neurological disorders to the Asian region. In recent years, YAFO has successfully concluded dozens of pharma and biotech cross-border transactions."

Sean Jiang, Founder and CEO of YAFO, added, "We are pleased to partner with BetterLife Pharma on the advancement of BETR-001 into the Greater China region. The non-hallucinogenic profile of BETR-001 represents a highly differentiated approach in neurological therapeutics, with significant clinical and commercial potential. Through this collaboration, YAFO will leverage its deep expertise and strong pharmaceutical network to accelerate strategic partnering and development opportunities for BetterLife in Asia."

BETR-001, a potent neuroplastogen, is BetterLife's patented stereoisomer of 2-bromo-LSD, a non-hallucinogenic derivative of LSD under development for the potential treatment of traumatic brain injury, post-traumatic stress disorder and cluster headache. Previous forms of 2-bromo-LSD has been shown to be non-hallucinogenic, safe and tolerable in man, and in a small clinical study, to cause meaningful reduction in cluster headache frequency (Karst et al, Cephalgia 2010).

**About YAFO Capital**

Founded in 2013, YAFO Capital is a Shanghai-based boutique investment and advisory firm, with professional teams in China, United States, European Union and Southeast Asia. Partnering with pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. Over the past five years, YAFO has been a leader in advising on China cross border licensing transactions.

For more information, please visit <u>www.yafocapital.com</u>.

1<br>

**About BetterLife Pharma** 

BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing BETR-001 to treat various neurological disorders. BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. BetterLife's synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of various neurological disorders, until around 2042.

BetterLife also owns a drug candidate for the treatment of viral infections and is in the process of seeking strategic alternatives for further development.

For further information, please visit <u>BetterLife Pharma</u>.

**Contact**

Ahmad Doroudian, Chief Executive Officer

Email: <u>Ahmad.Doroudian@blifepharma.com</u>

Phone: 1-604-221-0595

Wendi Xiang, Vice President

Email: <u>wxiang@yafocapital.com</u>

Phone: +86-13733685995

**Cautionary Note Regarding Forward-Looking Statements**

No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

2<br>

## Exhibit 99.8

**EXHIBIT 99.8**

![](betrf_ex998img1.jpg)

**BetterLife Pharma Highlights Advantages of BETR-001 – a Potent Neuroplastogen**

VANCOUVER, British Columbia, December 4, 2025 - BetterLife Pharma Inc. ("BetterLife" or the "Company") (<u>CSE: BETR</u> / <u>OTCQB: BETRF</u> / FRA: <u>NPAU</u>), an emerging biotech company, focused on development of BETR-001, its proprietary non-hallucinogenic derivative of lysergic acid diethylamide ("LSD").

Following recent news from a Phase 2 trial showing LSD microdosing is ineffective for depression, BetterLife highlights BETR-001's advantages over LSD. BETR-001 remains non-hallucinogenic even at high doses, as shown in our previous <u>publication</u>, and does not induce tolerance with repeated use, meaning that BETR-001 can be dosed on a chronic or repeated basis. Preclinical studies indicate that neuroplastogenic effects require sufficient dosing. Since BETR-001 can be administered at full dose without hallucinations, it maintains its effectiveness following repeated dosing.

Dr. Ahmad Doroudian, CEO of BetterLife, commented, "The importance of being able to give full doses of BETR-001 without hallucinations cannot be over-emphasized. Microdosing of psychedelics is often touted as the path forward to avoid the hallucinations of psychedelics full dosing and the need for treatment in specialized clinics with monitoring under special treatment protocols, which require in-clinic time of 8 to 12 hours. BETR-001 overcomes all these hurdles and can be administered at its full effective dose without any hallucinations."

Dr. Doroudian further commented, "We are completing the last remaining BETR-001 IND-enabliing studies and plan to file the IND and begin human clinical trials by 2H 2026. Our initial scope is to develop BETR-001 for treatment of Traumatic Brain Injury ("TBI"), cluster headaches and migraine. BETR-001 also has potential for treatment of a broad range of psychiatric disorders and they will also be explored as the compound's development life cycle moves forward."

**About BetterLife Pharma** 

BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing BETR-001 to treat various neurological disorders. BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. BetterLife's synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of various neurological disorders, until around 2042.

BetterLife also owns a drug candidate for the treatment of viral infections and is in the process of seeking strategic alternatives for further development.

For further information, please visit <u>BetterLife Pharma</u>.

**Contact**

Ahmad Doroudian, Chief Executive Officer

Email: Ahmad.Doroudian@blifepharma.com

Phone: 1-604-221-0595

**Cautionary Note Regarding Forward-Looking Statements**

No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

## Exhibit 99.9

**EXHIBIT 99.9**

**FORM 51-102F3**

**MATERIAL CHANGE REPORT**

---

| |
|:---|
| **Item 1**  |
| <br> BetterLife Pharma Inc. (the "Company")<br> 1275 West 6<sup>th</sup> Avenue<br> Suite 300<br> Vancouver, British Columbia<br> V6H 1A6 |

---

---

| | |
|:---|:---|
| **Item 2**  | **Date of Material Change** |
|  | November 25, 2025 |
| **Item 3**  | **News Releases** |
|  | News releases dated October 21, November 14 and November 25, 2025 |
| **Item 4**  | **Summary of Material Change** |
|  | On November 25, 2025, the Company announced announce Daniel Carcillo will join the Company as Corporate Advisor to advance BetterLife's BETR-001 development with focus on Traumatic Brain Injury ("TBI"), cluster headache and migraine. Mr. Carcillo is a Canadian former professional hockey left winger who won two Stanley Cups as a member of the Chicago Blackhawks of the National Hockey League ("NHL"). He was forced to retire at the age of 30 due to Post Concussion Syndrome after seven concussions. After retiring from the NHL in 2015, Mr. Carcillo created a non-profit organization that assists former NHL-players suffering from post-concussion syndrome and mental health issues. A well-known speaker and advocate on behalf of TBI survivors and people dealing with mental health challenges, Mr. Carcillo was the founder and CEO of Wesana Health, a life sciences company that leverages psilocybin-based medicine to treat traumatic brain injuries. |
|  | Also in November 2025, Mr. Mr. André Beaudry resigned from the Company's Board of Directors. |
|  | On October 21, 2025, the Company announced that it appointed Doug Drysdale, former CEO of Cybin Inc. ("Cybin") (NYSE: CYBN) as Corporate Advisor to advance BetterLife's product BETR-001's non psychiatric indications with focus on cluster headache and migraine. At Cybin, Mr. Drysdale led the company's strategy and team build-out, taking it from molecule inception to Phase 3 trials in just three years. Mr. Drysdale is known as a vocal advocate for revolutionizing mental healthcare through numerous speaking engagements, panel participations, and media interviews. Earlier in his career, as Founding CEO of Alvogen, Mr. Drysdale grew the company from inception to $500 million in revenues across 35 countries in 5.5 years, establishing research and development ("R&D") in New Jersey, a CRO in India, and a 50-product U.S. pipeline. In 2008, he transformed Norwich Pharmaceuticals, enhancing its manufacturing and R&D. In 2014, as Chairman and CEO of Pernix Therapeutics, Mr. Drysdale recapitalized the company with $65 million, rebuilt its leadership, and grew its enterprise value from $80 million to $800 million, raising $465 million to support the turnaround. From 2017–2020, as CEO of Tedor Pharma, he achieved 60% revenue growth in 2019, landing it on the 2020 Inc 5000 list |

---

---

| |
|:---|
| On September 30, 2025, the Company issued 57,945 common shares and 57,945 share purchase warrants pursuant to the conversion of accrued interest on convertible debentures totaling $5,794.52. Share purchase warrants are exercisable into common shares, on a one-for-one basis, at an exercise price of $0.10 per warrant and expire on September 27, 2026. |
| On September 26, 2025, the Company filed its condensed consolidated interim financial statements for the three and six months ended July 31, 2025 and 2024, along with its management's discussion and analysis, which can be accessed at <u>www.sedarplus.ca</u> |

---

---

| | |
|:---|:---|
| **Item 5**  | **Full Description of Material Change** |
|  | Refer to Item 4. |
| **Item 6**  | **Reliance on subsection 7.1(2) or (3) of National Instrument 51-102** |
|  | This Report is not being filed on a confidential basis in reliance on subsection 7.1(2) of National Instrument 51-102. |
| **Item 7**  | **Omitted Information** |
|  | No information has been omitted on the basis that it is confidential information. |
| **Item 8**  | **Executive Officer** |
|  | Further information can be obtained from Ahmad Doroudian, Chief Executive Officer of the Company, at (604) 221-0595. |
| **Item 9**  | **Date of Report** |
|  | December 2, 2025 |

---

**<u>SCHEDULE "A"</u>**

![](betrf_ex999img22.jpg)

**BetterLife Pharma Welcomes Daniel Carcillo as Corporate Advisor**

VANCOUVER, British Columbia, November 25, 2025 - BetterLife Pharma Inc. ("BetterLife" or the "Company") (<u>CSE: BETR</u> / <u>OTCQB: BETRF</u> / FRA: <u>NPAU</u>), an emerging biotech company, focused on development of BETR-001, its proprietary non-hallucinogenic derivative of LSD. BetterLife is pleased to announce Daniel Carcillo will join the Company as Corporate Advisor to advance BetterLife's BETR-001 development with focus on Traumatic Brain Injury ("TBI"), cluster headache and migraine.

Mr. Carcillo is a Canadian former professional hockey left winger who won two Stanley Cups as a member of the Chicago Blackhawks of the National Hockey League ("NHL"). He was forced to retire at the age of 30 due to Post Concussion Syndrome after seven concussions. After retiring from the NHL in 2015, Mr. Carcillo created a non-profit organization that assists former NHL-players suffering from post-concussion syndrome and mental health issues. A well-known speaker and advocate on behalf of TBI survivors and people dealing with mental health challenges, Mr. Carcillo was the founder and CEO of Wesana Health, a life sciences company that leverages psilocybin-based medicine to treat traumatic brain injuries.

Mr. Carcillo stated, "Joining BetterLife feels like the natural next step in my mission to help concussion survivors because we are advancing a medicine that carries the promise of psychedelic healing without the regulatory barriers and with all the serotonergic benefits people desperately need. I have lived the impact of brain trauma and I know how powerful these breakthroughs can be. This is about giving athletes veterans and anyone living with the invisible weight of concussion a real chance to heal and get their life back."

Dr. Ahmad Doroudian, CEO of BetterLife, commented, "We are very excited to have Mr. Carcillo joining our advisory group. His first hand experience with TBI and his passion to advance the development of medicines and treatments for those injuries will provide us with invaluable guidance. We look forward to working with Daniel to advance the development BETR-001."

**About BetterLife Pharma** 

BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing BETR-001 to treat various neurological disorders. BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. BetterLife's synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of various neurological disorders, until around 2042.

BetterLife also owns a drug candidate for the treatment of viral infections and is in the process of seeking strategic alternatives for further development.

For further information, please visit <u>BetterLife Pharma</u>.

**Contact**

Ahmad Doroudian, Chief Executive Officer

Email: <u>Ahmad.Doroudian@blifepharma.com</u>

Phone: 1-604-221-0595

**Cautionary Note Regarding Forward-Looking Statements**

No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

![](betrf_ex999img23.jpg)

**BetterLife Pharma Announces Debt Conversions**

VANCOUVER, British Columbia, November 14, 2025 - BetterLife Pharma Inc. ("BetterLife" or the "Company") (<u>CSE: BETR</u> / <u>OTCQB: BETRF</u> / FRA: <u>NPAU</u>), an emerging biotech company, announces that it has issued 57,945 common shares and 57,945 share purchase warrants in connection with the conversion of accrued interest on convertible debentures totaling $5,795. Each share purchase warrant entitles the holder to acquire one common share at an exercise price of $0.10 per share and will expire on September 27, 2026.

The Company also announces the resignation of Mr. André Beaudry from its Board of Directors and will be announcing appointment of new Corporate Advisor(s) in the coming weeks.

**About BetterLife Pharma** 

BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing BETR-001 to treat various neurological disorders. BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. BetterLife's synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of various neurological disorders, until around 2042.

BetterLife also owns a drug candidate for the treatment of viral infections and is in the process of seeking strategic alternatives for further development.

For further information, please visit <u>BetterLife Pharma</u>.

**Contact**

Ahmad Doroudian, Chief Executive Officer

Email: <u>Ahmad.Doroudian@blifepharma.com</u>

Phone: 1-604-221-0595

**Cautionary Note Regarding Forward-Looking Statements**

No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

![](betrf_ex999img24.jpg)

**BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor**

VANCOUVER, British Columbia, October 21, 2025 - BetterLife Pharma Inc. ("BetterLife" or the "Company") (<u>CSE: BETR</u> / <u>OTCQB : BETRF</u> / FRA: <u>NPAU</u>), an emerging biotech company, has announced that it has appointed Doug Drysdale, former CEO of Cybin Inc. ("Cybin") (NYSE: CYBN) as Corporate Advisor to advance BetterLife's product BETR-001's non psychiatric indications with focus on cluster headache and migraine.

At Cybin, Mr. Drysdale led the company's strategy and team build-out, taking it from molecule inception to Phase 3 trials in just three years. Mr. Drysdale is known as a vocal advocate for revolutionizing mental healthcare through numerous speaking engagements, panel participations, and media interviews.

Earlier in his career, as Founding CEO of Alvogen, Mr. Drysdale grew the company from inception to $500 million in revenues across 35 countries in 5.5 years, establishing research and development ("R&D") in New Jersey, a CRO in India, and a 50-product U.S. pipeline. In 2008, he transformed Norwich Pharmaceuticals, enhancing its manufacturing and R&D. In 2014, as Chairman and CEO of Pernix Therapeutics, Mr. Drysdale recapitalized the company with $65 million, rebuilt its leadership, and grew its enterprise value from $80 million to $800 million, raising $465 million to support the turnaround. From 2017–2020, as CEO of Tedor Pharma, he achieved 60% revenue growth in 2019, landing it on the 2020 Inc 5000 list.

Dr. Ahmad Doroudian, CEO of BetterLife, commented, "We are excited to welcome Doug to our advisory team. He is a globally recognized leader and strategist with over 35 years experience delivering multiple successful transactions in various different markets and indications. We look forward to working with Doug to develop BETR-001for treatment of cluster headache, migraine and neuropathic pain. BETR-001 is BetterLife's patented stereoisomer of 2-bromo-LSD, a non-hallucinogenic derivative of LSD. Previous forms of 2-bromo-LSD have been shown to be non-hallucinogenic, safe and tolerable in man, and in a small clinical study, to cause meaningful reduction in cluster headache frequency (<u>Karst et al, Cephalgia 2010</u>).

**About BetterLife Pharma** 

BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing BETR-001 to treat various neurological disorders. BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. BetterLife's synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of various neurological disorders, until around 2042.

BetterLife also owns a drug candidate for the treatment of viral infections and is in the process of seeking strategic alternatives for further development.

For further information, please visit <u>BetterLife Pharma</u>.

**Contact**

David Melles, Investor Relations Manager

Email: <u>David.Melles@blifepharma.com</u>

Phone: 1-778-887-1928

**Cautionary Note Regarding Forward-Looking Statements**

No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.